Ernexa Therapeutics Inc. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Ernexa Therapeutics Inc. (ERNA) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $10.00 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-13.
Discontinued › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2020-11-13
- Ernexa Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2020-03-31 was -$71.00K, a 473.68% decline year-over-year.
- Ernexa Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2019-03-31 was $19.00K.
- Ernexa Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2018-03-31 was -$25.00K.
- Ernexa Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2019 was $42.00K.
- Ernexa Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2018 was -$75.00K, a 219.05% decline from fiscal 2017.
- Ernexa Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2017 was $63.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2020-09-30 | $10.00K 10-Q · filed 2020-11-13 | |||
| 2020-06-30 | $6.00K 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | -$71.00K 10-Q · filed 2020-05-20 | |||
| 2019-12-31 | $42.00K 10-K · filed 2020-03-19 | |||
| 2019-09-30 | $27.00K 10-Q · filed 2020-11-13 | |||
| 2019-06-30 | $39.00K 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | $19.00K 10-Q · filed 2020-05-20 | |||
| 2018-12-31 | -$75.00K 10-K · filed 2020-03-19 | |||
| 2018-09-30 | -$28.00K 10-Q · filed 2019-11-01 | |||
| 2018-03-31 | -$25.00K 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | $63.00K 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |